An official website of the United States government

Publication Information

PubMed ID
Public Release Type
Journal
Publication Year
2021
Authors
Soomro Sanam, Venkateswaran Suresh, Vanarsa Kamala, Kharboutli Marwa, Nidhi Malavika, Susarla Ramya, Zhang Ting, Sasidharan Prashanth, Lee Kyung Hyun, Rosh Joel, Markowitz James, Pedroza Claudia, Denson Lee A., Hyams Jeffrey, Kugathasan Subra, Mohan Chandra
Studies

Abstract

In the search for improved stool biomarkers for inflammatory bowel disease (IBD), an aptamer-based screen of 1129 stool proteins was conducted using stool samples from an IBD cohort. Here we report that of the 20 proteins subsequently validated by ELISA, stool Ferritin, Fibrinogen, Haptoglobin, Hemoglobin, Lipocalin-2, MMP-12, MMP-9, Myeloperoxidase, PGRP-S, Properdin, Resistin, Serpin A4, and TIMP-1 are significantly elevated in both ulcerative colitis (UC) and Crohn’s disease (CD) compared to controls. When tested in a longitudinal cohort of 50 UC patients at 4 time-points, fecal Fibrinogen, MMP-8, PGRP-S, and TIMP-2 show the strongest positive correlation with concurrent PUCAI and PGA scores and are superior to fecal calprotectin. Unlike fecal calprotectin, baseline stool Fibrinogen, MMP-12, PGRP-S, TIMP-1, and TIMP-2 can predict clinical remission at Week-4. Here we show that stool proteins identified using the comprehensive aptamer-based screen are superior to fecal calprotectin alone in disease monitoring and prediction in IBD.